Theralase Technologies Inc. V.TLT

SO IM MISSING THE GOOD NEWS

[gonefishing2022]

Can Anyone explain what this exciting news is and the share price goes down and I don't have pie in the sky evaluation. I don't see this going 2 dollars anytime soon. Also I don't really see a change until 2026..

Go Tell Me I'm wrong

[Beano349]

The good news was the new 450 CR tracking of over 40%. 1 treatment, and a CR over 40 over 1 year later. That's a big deal, but we still need approval...

[CancerSlayer]

Good news today... To be clear, a DOR% is different than a CR% at a given point in time.  A DOR% refers to the % of responders who have maintained their response over a given period or "duration" of time.  A CR% reflects the total number of responders out of the total number treated at any given "point" in time. The 44% 450 day number reported is referring to a DOR

[Oden6570]

As well only 1 or 2 treatments as an outpatient 

[Lesalpes29]

Good results (we have already) + money for at least one year and I will be on the buy side. GL

[CancerSlayer]

Indeed...and one should not overlook the fact that there is a general doctor shortage, which is a growing & relatively hidden healthcare crisis.  In the clinic, there are too many docs currently working under a major time crunch.  Any protocol that requires fewer treatments will ultimately enable increased patient access & provide a doc more availability/time to treat another

[riverrrow]

Thank you and everyone for your posts.  I didn't look at the Swimmer's plot until now.  I count 9 patients CR at 2 years (which is 720 days).  I'm sure those patients are pretty happy about that.  I was hoping the news release was going to say this; 9 patients CR at 2 years.  Not everyone is a statistician and is going to study charts and graphs to gleam out

[Eoganacht]

If I'm reading it right, the swimmer's plot shows 6 CR's at 2 years. 1 of the 6 recurred at  27 months. But then there are another 10 or so patients who have hit (or almost hit) 2 years or more that Theralase has not yet received the 2 year data for. Plus there's 1 patient who was CR at 1.5 years who hasn't reached the 2 year evaluation yet. If all 16 are CR at 2 years

[DJDawg]

The new swimmers is interesting in a few ways. One thing that is new is that they are showing the dots and squares at the true time point date when happened. It makes sense that things never happen on the days exactly as there can be issues that arise. The explains why green dots and red squares are not a perfect line down at each time point. Eog, I find the plot confusing in one way. The grey

[Eoganacht]

Hi DJDawg - nice post. That all makes sense to me. I think it's possible the pending patients are ones for which Theralase has not yet received the post-450 day patient permission forms. Your analysis sounds right to me. It's excitng to contemplate the possibility that 25% of all patients treated are cancer free at 3 years! Theralase will be able to claim that one quarter of all patents

[CancerSlayer]

I also agree, but my conservative nature puts us at 20-25% cancer-free at 2 to 3 years ; ).  However, I expect with more experience & refinements being made over time, these percentages should rise, especially as our newer & preclinically more promising organometallic compounds get integrated.   Considering our tech's versatility, synergistic capabilities, low treatment

[menoalittle]

So, here's a question for anyone with a reasonably good sense of how things can or might go with possible designations and approvals for the intravesicular use of TLD-1433 with NMIBC... How quickly can or might TLD-1433 be adapted and approved for similar use on colon cancer?  I'm inclined to think (or at least, would like to believe and hope) that it ought to be much quicker and

[menoalittle]

After all... look at the stats for colon cancer: Colorectal cancer is the third most common cancer worldwide, accounting for approximately 10% of all cancer cases and is the second leading cause of cancer-related deaths worldwide

[DJDawg]

This would require IV therapy with rutherrin which is a different compount. So ruvidar, approved, can't jump from bladder med to IV med. Good thought. The big plan would be to show efficacy at gbm and nsclc and then at that point you could tally up approvals for just about any cancer that likes iron (they all do, especially solid ones).

[bigkagan]

I wonder if somebody from the company got cancer would he use rutherrin with x-rays on himself even without any permits

[Tarbaby]

Very good point...using xray pdt. That is likely the most valuable asset TLT.v has. Its a sleeping giant that should be out there curing cancer. If I had incurable cancer I would try using other pdt compounds combined with xrays. There are a few such compounds I believe.

[CancerSlayer]

Had a couple of minor corrections for an earlier post.....There were 2 patients who had not yet reached the 450 day mark, which changes the denominator to 63 (not 65). "The 450 day CR would be 18 out of a total of 65 patients treated (or ~28% CR at 450 days)." Correction:  The 450 day CR would be 18 out of a total of 63 patients treated (or ~29% CR at 450 days).   "

[Eoganacht]

Good post CancerSlayer - the one quibble I would have is with the number of patients currently considered evaluable at 450 days. If you look at the news release from May 30 - (2 1/2 months ago) - the number of patients evaluable at 450 days is 57. https://stockhouse.com/news/press-releases/2024/05/30/theralase-r-release-s-1q2024-financial-statements If you look at the swimmers plot of the same

[CancerSlayer]

You are correct...thanks for pointing that out Eoganacht. Definitely every percentage point counts every patient's sake.  I am looking forward (perhaps foolishly ; ) to the day the data can be more easily interpreted from a single graphical representation.   The need to refer back to other releases/graphs to more accurately decipher numbers is getting a bit nauseating...at least for

[Eoganacht]

I have a hunch we're going to see the DOR format from now on. It"s the way all of our competition presents their data. Maybe this was a suggestion from the biostatistics organization which is helping with the BTD application.

[Donein25]

From what you are saying; it sounds like in approximately 9 months time we will have about 60 folks evaluable at 2 years?

[DJDawg]

One thing that impacts how the data is interpreted for things like AA is if you consider that most of the CR patients on the swimmers are at 630 and past. There are 3 that are further back in time. IF you assume that the 3 newest CRs all recur and therefore are not long term responders. That means that you in 4months all the other CR's will be at 2yrs or further. In 4m they will be able to

[Donein25]

I see where you are going with this Dawg. It sort of ties in to what I said earlier about the significance of "75 patients". Roger stated this week that we have already met all 3 endpoints. So the 2 year data and 75 patients really is not about BTD, its beyond that. (Immuno got BTD in 2019 just by hitting its first endpoint)

[DJDawg]

What would be great is if the application got a boost from duration of response AFTER last treatment, maintenance event. For Anktiva+BCG the protocol is such that you get 3, weekly maintenance instillations every 6months, ongoing. You finish the every 3m schedule at month 13 and then go to every 6m. So you never really have pure CR since last event since it never really stops.   For

[Lesalpes29]

The act is safe, with good or very good results. FDA will give us pre-BTD and BTD this year (it's my bet). The real 2024 Christmas gift could be AA, we can dream. GL